Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Myeloid leukemia after hematotoxins.
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Myeloid leukemia after hematotoxins.
Myeloid leukemia after hematotoxins. Environ Health Perspect. 1996 Dec; 104 Suppl 6:1303-7.
View in:
PubMed
subject areas
Antineoplastic Agents, Alkylating
Bone Marrow
Chromosomes, Human, Pair 11
Chromosomes, Human, Pair 21
Humans
Leukemia, Myeloid
Mutation
Neoplasms, Second Primary
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Time Factors
Topoisomerase II Inhibitors
Translocation, Genetic
authors with profiles
Richard A. Larson
Michelle M. Lebeau
James W. Vardiman